Zenas BioPharma Prices $200 Million Convertible Notes Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ZBIO?
Source: Newsfilter
- Funding Size: Zenas BioPharma announced a public offering of 5 million shares at $20.00 each and $200 million in 2.50% convertible senior notes, with estimated net proceeds of approximately $287.5 million, significantly strengthening the company's capital base for future growth.
- Bond Terms: The convertible notes will mature in 2032 with a 2.50% interest rate and allow conversion under specific conditions, featuring an initial conversion price of about $26.50 per share, representing a 32.5% conversion premium, enhancing investor appeal.
- Use of Proceeds: Zenas intends to utilize the proceeds to support the U.S. commercial launch of obexelimab and advance orelabrutinib clinical trials, demonstrating confidence in its product pipeline and responsiveness to market demand.
- Underwriter Lineup: Jefferies, Evercore ISI, Citigroup, and Guggenheim Securities are acting as joint book-running managers for the offerings, indicating strong market trust in Zenas and recognition of its future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZBIO
Wall Street analysts forecast ZBIO stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 22.190
Low
19.00
Averages
41.20
High
55.00
Current: 22.190
Low
19.00
Averages
41.20
High
55.00
About ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zenas BioPharma Prices $200 Million Convertible Notes Offering
- Funding Size: Zenas BioPharma announced a public offering of 5 million shares at $20.00 each and $200 million in 2.50% convertible senior notes, with estimated net proceeds of approximately $287.5 million, significantly strengthening the company's capital base for future growth.
- Bond Terms: The convertible notes will mature in 2032 with a 2.50% interest rate and allow conversion under specific conditions, featuring an initial conversion price of about $26.50 per share, representing a 32.5% conversion premium, enhancing investor appeal.
- Use of Proceeds: Zenas intends to utilize the proceeds to support the U.S. commercial launch of obexelimab and advance orelabrutinib clinical trials, demonstrating confidence in its product pipeline and responsiveness to market demand.
- Underwriter Lineup: Jefferies, Evercore ISI, Citigroup, and Guggenheim Securities are acting as joint book-running managers for the offerings, indicating strong market trust in Zenas and recognition of its future growth potential.
See More
Zenas BioPharma Launches Convertible Note Offerings
- Financing Initiative: Zenas BioPharma has commenced underwritten public offerings of convertible senior notes and common stock, maturing in 2032, which is expected to provide essential funding to advance its product development.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase an additional 15% of the convertible notes and common stock, a strategy that will enhance financing flexibility and attract more investors.
- Use of Proceeds: If the offerings are successfully completed, Zenas intends to use the net proceeds to support the U.S. commercial launch of obexelimab, pending approval, while advancing the Phase 3 clinical trials of orelabrutinib and the Phase 1 and 2 development of ZB021, demonstrating the company's commitment to new drug development.
- Market Reaction: Following the press release, ZBIO's stock price rose 0.09% in after-hours trading to $22.17, reflecting a positive market sentiment towards the company's financing plans and future growth prospects.
See More
ENAVATE Increases Stake in Zenas BioPharma
- Share Increase: On February 17, 2026, ENAVATE Sciences GP, LLC disclosed the purchase of 157,800 shares of Zenas BioPharma, with an estimated transaction value of approximately $5.19 million, reflecting the company's confidence in the biopharmaceutical firm.
- Value Growth: This transaction increased the quarter-end value of Zenas BioPharma's holdings by about $58.80 million, demonstrating the dual impact of share price appreciation and the purchase, further solidifying ENAVATE's investment position in the biotech sector.
- Asset Allocation Shift: Following the purchase, Zenas BioPharma accounted for 28.08% of ENAVATE's reportable AUM, making it the fund's largest holding, indicating an increasing emphasis on this stock by the company.
- Future Outlook: Zenas BioPharma plans to submit a BLA for obexelimab to the FDA in Q2 2026, which, if successful, could significantly enhance the company's market position, and ENAVATE's continued investment reflects confidence in its future development.
See More
Zenas BioPharma Reports Q4 EPS Miss and Cash Projections
- Disappointing Earnings: Zenas BioPharma reported a Q4 GAAP EPS of -$4.54, missing expectations by $3.66, indicating significant challenges in profitability that may undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $360.5 million in cash, cash equivalents, and investments, which is projected to fund operating and capital expenditures into Q2 2027, reflecting a degree of financial management capability.
- Future Funding Outlook: Assuming receipt of $75 million from Pharmakon-managed investment funds and another $75 million from Royalty Pharma contingent on FDA approval of obexelimab, the company expects to sustain its cash position into Q4 2027, demonstrating optimism about future cash inflows.
- Market Reaction: Despite the CEO's over $1 million stock purchase, the market's disappointment over late-stage trial data led to a significant stock price drop, indicating investor concerns about the company's future prospects.
See More
Purcell & Lefkowitz Investigates Zenas BioPharma for Potential Fiduciary Breaches
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Zenas BioPharma to determine whether the company's directors breached their fiduciary duties in recent corporate actions, potentially affecting shareholder rights.
- Shareholder Rights Focus: The investigation aims to protect Zenas BioPharma shareholders, with the law firm offering free consultations to ensure shareholders are informed about their rights and options, thereby enhancing transparency in corporate governance.
- Legal Support: Purcell & Lefkowitz LLP specializes in representing shareholders nationwide in cases of securities fraud and breaches of fiduciary duty, demonstrating their commitment to safeguarding shareholder interests.
- Potential Impact: Should the investigation confirm misconduct by the board, Zenas BioPharma may face legal repercussions, which could undermine shareholder confidence and adversely affect the company's stock price.
See More
Zenas BioPharma Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Zenas BioPharma investors regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious governance concerns.
- Disappointing Trial Results: Zenas's January 5, 2026 announcement of 'positive' results from the INDIGO trial was met with skepticism as analysts noted the drug's efficacy likely fell short of commercial viability thresholds, potentially impacting future sales prospects.
- Stock Price Volatility: Following the trial results, Zenas's stock plummeted by 51.86% to $16.61 per share on January 5, 2026, and further declined by 8.49% to $15.20 per share the next day, reflecting a pessimistic market outlook on the company's future.
- CEO Acknowledges Disappointment: During a conference call on January 6, 2026, Zenas's CEO expressed disappointment that the hazard ratio did not meet expectations, which may exacerbate investor concerns and lead to increased legal scrutiny.
See More
Zenas BioPharma Prices $200 Million Convertible Notes Offering
- Funding Size: Zenas BioPharma announced a public offering of 5 million shares at $20.00 each and $200 million in 2.50% convertible senior notes, with estimated net proceeds of approximately $287.5 million, significantly strengthening the company's capital base for future growth.
- Bond Terms: The convertible notes will mature in 2032 with a 2.50% interest rate and allow conversion under specific conditions, featuring an initial conversion price of about $26.50 per share, representing a 32.5% conversion premium, enhancing investor appeal.
- Use of Proceeds: Zenas intends to utilize the proceeds to support the U.S. commercial launch of obexelimab and advance orelabrutinib clinical trials, demonstrating confidence in its product pipeline and responsiveness to market demand.
- Underwriter Lineup: Jefferies, Evercore ISI, Citigroup, and Guggenheim Securities are acting as joint book-running managers for the offerings, indicating strong market trust in Zenas and recognition of its future growth potential.
See More
Zenas BioPharma Launches Convertible Note Offerings
- Financing Initiative: Zenas BioPharma has commenced underwritten public offerings of convertible senior notes and common stock, maturing in 2032, which is expected to provide essential funding to advance its product development.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase an additional 15% of the convertible notes and common stock, a strategy that will enhance financing flexibility and attract more investors.
- Use of Proceeds: If the offerings are successfully completed, Zenas intends to use the net proceeds to support the U.S. commercial launch of obexelimab, pending approval, while advancing the Phase 3 clinical trials of orelabrutinib and the Phase 1 and 2 development of ZB021, demonstrating the company's commitment to new drug development.
- Market Reaction: Following the press release, ZBIO's stock price rose 0.09% in after-hours trading to $22.17, reflecting a positive market sentiment towards the company's financing plans and future growth prospects.
See More
ENAVATE Increases Stake in Zenas BioPharma
- Share Increase: On February 17, 2026, ENAVATE Sciences GP, LLC disclosed the purchase of 157,800 shares of Zenas BioPharma, with an estimated transaction value of approximately $5.19 million, reflecting the company's confidence in the biopharmaceutical firm.
- Value Growth: This transaction increased the quarter-end value of Zenas BioPharma's holdings by about $58.80 million, demonstrating the dual impact of share price appreciation and the purchase, further solidifying ENAVATE's investment position in the biotech sector.
- Asset Allocation Shift: Following the purchase, Zenas BioPharma accounted for 28.08% of ENAVATE's reportable AUM, making it the fund's largest holding, indicating an increasing emphasis on this stock by the company.
- Future Outlook: Zenas BioPharma plans to submit a BLA for obexelimab to the FDA in Q2 2026, which, if successful, could significantly enhance the company's market position, and ENAVATE's continued investment reflects confidence in its future development.
See More
Zenas BioPharma Reports Q4 EPS Miss and Cash Projections
- Disappointing Earnings: Zenas BioPharma reported a Q4 GAAP EPS of -$4.54, missing expectations by $3.66, indicating significant challenges in profitability that may undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $360.5 million in cash, cash equivalents, and investments, which is projected to fund operating and capital expenditures into Q2 2027, reflecting a degree of financial management capability.
- Future Funding Outlook: Assuming receipt of $75 million from Pharmakon-managed investment funds and another $75 million from Royalty Pharma contingent on FDA approval of obexelimab, the company expects to sustain its cash position into Q4 2027, demonstrating optimism about future cash inflows.
- Market Reaction: Despite the CEO's over $1 million stock purchase, the market's disappointment over late-stage trial data led to a significant stock price drop, indicating investor concerns about the company's future prospects.
See More
Purcell & Lefkowitz Investigates Zenas BioPharma for Potential Fiduciary Breaches
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Zenas BioPharma to determine whether the company's directors breached their fiduciary duties in recent corporate actions, potentially affecting shareholder rights.
- Shareholder Rights Focus: The investigation aims to protect Zenas BioPharma shareholders, with the law firm offering free consultations to ensure shareholders are informed about their rights and options, thereby enhancing transparency in corporate governance.
- Legal Support: Purcell & Lefkowitz LLP specializes in representing shareholders nationwide in cases of securities fraud and breaches of fiduciary duty, demonstrating their commitment to safeguarding shareholder interests.
- Potential Impact: Should the investigation confirm misconduct by the board, Zenas BioPharma may face legal repercussions, which could undermine shareholder confidence and adversely affect the company's stock price.
See More
Zenas BioPharma Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Zenas BioPharma investors regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious governance concerns.
- Disappointing Trial Results: Zenas's January 5, 2026 announcement of 'positive' results from the INDIGO trial was met with skepticism as analysts noted the drug's efficacy likely fell short of commercial viability thresholds, potentially impacting future sales prospects.
- Stock Price Volatility: Following the trial results, Zenas's stock plummeted by 51.86% to $16.61 per share on January 5, 2026, and further declined by 8.49% to $15.20 per share the next day, reflecting a pessimistic market outlook on the company's future.
- CEO Acknowledges Disappointment: During a conference call on January 6, 2026, Zenas's CEO expressed disappointment that the hazard ratio did not meet expectations, which may exacerbate investor concerns and lead to increased legal scrutiny.
See More
